Fanconi Anaemia Treatment in India – Curative BMT with Reduced-Intensity Conditioning

Fanconi anaemia treatment in India from $15,000. Haematopoietic stem-cell transplant with RIC — the only cure — at expert paediatric haematology centres. 85%+ success rate.

Estimated cost: $15,000 – $28,000 · Average stay: 30–50 days

Fanconi anaemia (FA) is a rare inherited bone marrow failure syndrome caused by mutations in DNA repair genes (FANC gene family), resulting in progressive pancytopenia, congenital abnormalities, and very high risks of myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and solid tumours.

The only curative treatment is haematopoietic stem-cell transplantation (HSCT), replacing the defective bone marrow. Because FA cells are hypersensitive to DNA-crosslinking agents used in standard conditioning, reduced-intensity conditioning (RIC) with fludarabine-based regimens is essential to avoid fatal toxicity.

India's specialist FA transplant units at CMC Vellore and other premier centres have pioneered RIC approaches achieving survival rates of 80–90% in Class I/II patients — at $15,000–$28,000 versus $200,000–$400,000 in the US.

What is Fanconi Anaemia?

FA is caused by biallelic mutations in one of the 22 currently identified FANC genes that form a DNA damage repair pathway. The most common complementation group is FANCA (>60% of cases). FA cells accumulate chromosomal breaks when exposed to DNA crosslinking agents — the basis of the diagnostic diepoxybutane (DEB) and mitomycin-C (MMC) chromosomal breakage tests.

Clinical features include congenital abnormalities (absent radii, thumb anomalies, renal malformations, microcephaly, pigmentation changes), progressive bone marrow failure from childhood, and a dramatically elevated lifetime risk of squamous cell carcinoma of the head and neck, oesophagus, and gynaecological tract — regardless of transplant.

Who Should be Transplanted for Fanconi Anaemia?

Early transplant — before significant aplasia or clonal evolution — gives the best outcomes. Most FA specialists recommend HSCT when platelet count falls below 50,000/μL, haemoglobin below 8g/dL, or MDS features appear on marrow biopsy. Earlier transplant avoids transfusion alloimmunisation and disease progression. All FA patients should be HLA-typed as early as possible to allow timely donor identification and listing.

How is Fanconi Anaemia Treated with HSCT?

Diagnosis is confirmed by DEB chromosomal breakage test and FANC gene mutation panel. HLA typing of the patient and all available siblings is performed early — before significant marrow failure — to identify matched sibling donors when they exist. Androgen therapy (oxymetholone or danazol) temporarily stabilises blood counts as a bridge to transplant or in patients without a donor.

HSCT is indicated on progression to severe aplasia, MDS, or early AML transformation. RIC conditioning with fludarabine + low-dose cyclophosphamide ± antithymocyte globulin achieves engraftment with markedly lower toxicity than standard myeloablative conditioning. Post-transplant, lifelong head-and-neck cancer surveillance continues.

Procedure Steps

1. DEB or MMC chromosomal breakage test: confirms FA diagnosis by DNA hypersensitivity
2. FANC gene mutation panel: identifies specific complementation group
3. Bone marrow biopsy: assess aplasia severity, MDS features, cytogenetics
4. HLA typing of all available siblings and parents: identify matched donor early
5. Androgen therapy (oxymetholone/danazol): bridging treatment stabilising counts pre-transplant
6. Pre-transplant organ function: dental evaluation, ENT head-and-neck cancer screen, echo
7. RIC conditioning: fludarabine 150mg/m² + cyclophosphamide 10mg/kg ×4 + ATG
8. Stem cell infusion: matched sibling PBSC or BM (preferred); MUD or haploidentical if no sibling
9. Engraftment monitoring: daily CBC; chimerism at day +28, +100
10. GVHD prophylaxis: cyclosporine + short-course methotrexate or PTCy protocol
11. Lifelong post-transplant surveillance: annual head-and-neck screening; gynaecological screening

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

India — $15,000 – $28,000 — Save 93%

UAE — $80,000 – $180,000 — Save 83%

United States — $200,000 – $400,000 — —

United Kingdom — $120,000 – $250,000 — —

India's specialist FA-BMT programmes achieve outcomes comparable to leading Western centres at 85–93% lower cost. Figures include pre-transplant evaluation, RIC conditioning, stem-cell infusion, 30–50-day hospital stay, and initial post-transplant monitoring. Androgen bridging therapy costs $200–$500/month.

Recovery & Follow-up

Engraftment with RIC conditioning typically occurs at days 14–21. Total hospital stay is 30–50 days; outpatient follow-up nearby for a further 30–60 days before returning home. Immunosuppression is tapered over 6–12 months. Regular head-and-neck cancer surveillance and gynaecological screening continue lifelong after transplant.

Recovery Tips

• HLA typing of all siblings should be done at diagnosis — do not wait until aplasia is severe.
• Maintain androgen therapy compliance as a bridge to transplant if prescribed.
• Post-BMT, attend all head-and-neck cancer surveillance appointments annually for life.
• Avoid tobacco and alcohol — both dramatically increase head-and-neck SCC risk in FA patients.
• HPV vaccination before sexual activity is strongly recommended — FA patients have elevated HPV-related cancer risk.

Risks & Complications

FA-specific risks include conditioning toxicity (RIC substantially reduces this), rejection (5–10% in MUD/haploidentical), GVHD, and infection during aplastic period. Graft failure is more common in FA than in non-FA BMT but is manageable with second transplant in some cases. The most important long-term risk is solid tumour development — head and neck squamous cell carcinoma occurs in 10–15% of FA survivors by age 40, regardless of transplant.

Why GAF Healthcare

Gaf Healthcare connects families with India's specialist FA-BMT centres, coordinates pre-travel gene mutation analysis and early HLA sibling typing, provides accommodation for the entire family near the BMT unit for the 2–3 month stay, and prepares a lifelong solid tumour surveillance plan for post-transplant care in the patient's home country.

Frequently Asked Questions

At what age should a child with Fanconi anaemia be transplanted?

Early transplant before significant aplasia or clonal evolution gives the best outcomes. HSCT is typically recommended when platelet count falls below 50,000/μL or MDS features appear on marrow biopsy — usually under 10 years.

Why can't standard conditioning be used for Fanconi anaemia BMT?

FA cells have defective DNA repair and are hypersensitive to standard busulfan and cyclophosphamide doses — causing fatal mucositis and organ damage. RIC with low-dose fludarabine and cyclophosphamide achieves engraftment safely.

What if no sibling donor is available?

MUD from international registries (DKMS, NMDP) and haploidentical parent donors using PTCy are viable options with improving outcomes at experienced Indian FA-BMT centres.

Does BMT cure Fanconi anaemia completely?

BMT cures the bone marrow failure and eliminates leukaemia risk from haematopoietic tissue. It does not correct FA in other body cells — so the elevated solid tumour risk persists lifelong, requiring regular cancer surveillance.

How does Gaf Healthcare support Fanconi anaemia BMT families?

We coordinate pre-travel gene mutation analysis, early HLA typing of siblings, hospital listing, family accommodation near the BMT unit, and a lifelong surveillance plan for post-transplant solid tumour screening.